The chemoresistance observed in lung cancer patients harboring KRAS oncogenic mutations was suggested to be the consequence of KRAS mediated upregulation of NRF2 transcription factor, an oncogenic hub of oxidative stress response [88]. Here, KRAS is linked to lung cancer.